Drugs / mRNA-1045
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05585632 | Oct 2022 → Feb 2024 | Orthocoronavirinae infectious disease, influenza, respiratory syncytial virus infectious disease | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05606965 | Nov 2022 → Nov 2025 | influenza | ModernaTX, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1045 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05606965 ↗ |
| Route | Intramuscular | “by IM injection” NCT05606965 ↗ |